— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected.
— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.
— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago.
— MTNB shares ended down 2.75% in its last trading session on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: Key highlights from Campbell Soup Company’s (CPB) Q1 2023 earnings results
Campbell Soup Company (NYSE: CPB) reported first quarter 2023 earnings results today. Net sales increased 15% year-over-year to $2.57 billion. Organic sales growth was 15%. Net earnings attributable to Campbell Soup
Cancer drug maker Felicitex prepares for IPO. Here’s all you need to know
Fewer companies filed for initial public offering this year, compared to 2021 when the market witnessed a record number of IPOs. With only a few weeks left for the year
Chipotle Mexican Grill (CMG): A few points to keep in mind if you have an eye on this restaurant chain
Shares of Chipotle Mexican Grill Inc. (NYSE: CMG) were down 3% on Tuesday. The stock has dropped 13% year-to-date but there is still a positive sentiment in general about its
